The new Amass app is live. Ask in plain language, check every claim. Try it free

Skills & Prompts

Run Amass in any assistant

Paste-ready prompts and packaged skills that turn Amass into finished analyst work in Claude, Codex, Copilot, or any MCP-compatible assistant. Each carries a real, validated answer and downloadable take-home files, and needs no build or deploy.

Topic
Mode
Output

13 items

pdf+1
196trials in scope
Landscape Monitor — page 1
competitive-intelligenceSkillFeatured

Landscape Monitor

Name a field; get it mapped across trials, papers, patents, drugs, genes and approvals into a landscape page with charts, a workbook and a one-page briefing, every record screened with its reason. Ask for an update later to see what is new and what changed.

Open showcase
xlsx
14trials watched
Short nameSource idRegistryCopy of
Acute, 50/75 mg vs placeboNCT04072354ClinicalTrials.gov
↳ EUCTR2019-000470-36-BGEU CTRNCT04072354
Acute, 75/100 mg vs placeboNCT04092686ClinicalTrials.gov
competitive-intelligenceSkill

Watchlist Monitor

Name the trials, papers, approvals or drugs you need to follow; get one Excel board that re-reads them through Amass at every check and tells you exactly what changed: status, dates, enrollment, results posted, label revisions, retractions, new links.

csv
12targets scored
kinasekinase_family_chembl_leafsmall_molecule_tractabilityprotac_tractability
PLK1Other protein kinase PLK familyAdvanced Clinicalpredictive-only
WEE1Other protein kinase WEE familyAdvanced Clinicalpredictive-only
CDK1CMGC protein kinase CDK5 subfamilyAdvanced Clinicalpredictive-only
researchSkill

Target prioritization matrix

A general, interview-driven target-discovery workbench: name the biology and the modality you care about, and get back a scored table of candidate targets — druggability, essentiality, genetic constraint, curated safety, and the real number of drugs already targeting each — assembled from GeneCore intelligence and DrugCore/TrialCore/BiomedCore/PatentCore cross-links.

csv
2approved, first-gen
record_typetitleidsource
paperMechanisms of Resistance to KRASG12C InhibitorsPMID:33466360Cancers (JuFo 2)
paperOncogenic KRAS blockade therapy: renewed enthusiasm and persistent challengesPMID:34607583Molecular Cancer (JuFo 3)
paperKRAS G12C Mutations in NSCLC: From Target to ResistancePMID:34064232Cancers (JuFo 2)
competitive-intelligenceSkill

Biomedical Evidence Scout

Name a drug, target, mechanism, or indication; get a landscape briefing that maps the published literature AND the clinical pipeline together — every paper and trial carrying a real Amass ID, PMID, or NCT you can check.

csv+1
7linked papers
ranktitlejournalpublicationDate
1Efficacy and Safety of NVX-CoV2373 in Adults in the United States and MexicoThe New England journal of medicine2022-02-10
2Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical TrialJAMA network open2023-04-03
3Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 TrialmedRxiv (preprint)2022-09-21
clinical-evidenceSkill

Trial evidence trace

Paste one clinical-trial ID; get the exact published papers that describe it — pulled from Amass's publication↔trial graph, with trust metadata and abstract-grounded relevance notes.

docx
5Phase-3 trials

1. Pivotal Phase-3 program

AMASS EVIDENCE BRIEF

regulatoryPrompt

Tirzepatide evidence brief

Name a drug asset; get a citation-auditable Word evidence brief — pivotal Phase-3 trials, grounded efficacy and safety findings, and the trial↔paper links — every figure verbatim from Amass.

docx+1
6Phase-3 trials

EXPLORER-HCM - NCT03470545 (16 describing papers)

Submission Evidence Assembler - mavacamten (Camzyos)

regulatorySkill

Submission evidence assembler

Name one drug asset; get a citation-auditable, Module-2.5-style evidence narrative — every pivotal Phase-3 trial, its describing papers, and a canonical Amass-ID audit trail — assembled from Amass's publication↔trial graph with trust metadata on every cited paper.

pdf
2MAESTRO trials
Resmetirom evidence snapshot — page 1
researchPrompt

Resmetirom evidence snapshot

Name a drug asset; get a one-page PDF evidence snapshot — regulatory status, pivotal trials, grounded efficacy figures and the trial↔paper link — every number verbatim from Amass.

csv+1
10papers screened
PMIDAMBCtitlejournal
25037936AMBC_LgGUu4qEoXy99ZBBdZt6kLYpaq9Modeling and research on researchClinical chemistry
29534060AMBC_VRlhiy7cmm9d5q13WjyMr2UA9I0Meta-research: Why research on research mattersPLoS biology
15878467AMBC_Mk6C6o15EdZyjpf9Pl1vmAoKBozEarly extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trialsJournal of clinical epidemiology
research-integritySkill

ORCID record self-verify

Paste your own ORCID; get the publication record Amass indexes under that verified identity, screened in one pass for retractions, below-peer-review journals, and trial linkage — a clean integrity self-audit before a grant, tenure, or promotion submission.

xlsx
10papers
KOL paper-trial triangulator — Mikhail Kosiborod · query "cardiometabolic heart failure"
Top-10 by relevance (sample, not the full oeuvre). Source: Amass BiomedCore authorNames seed + per-paper referencesTrialCore edge. 6/10 trial-linked, 4/10 (meta-analyses/reviews) none. 0 retracted.
paper_PMIDpaper_AMBCtitlejournal
35228754AMBC_7BiZMrt83VZHgdVwEesrmHqQ0MBThe SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (EMPULSE)Nature medicine
researchSkill

KOL paper-trial triangulator

Name a KOL plus a context query; get their top-10 most relevant papers, each triangulated to the exact clinical trial it reports — pulled from Amass's publication↔trial graph, with trust metadata and a downloadable engagement-dossier workbook.

xlsx
18Phase-3 trials
NCTacronymdrug (interventionNames)sponsor
NCT01051219FELINELosartanNewcastle-upon-Tyne Hospitals NHS Trust
NCT03053050STELLAR-3SEL; Placebo to match SEL 6 mg; Placebo to match SEL 18 mgGilead Sciences
NCT03900429MAESTRO-NASHMGL-3196; Placebo; Liver BiopsyMadrigal Pharmaceuticals, Inc.
competitive-intelligenceSkill

Indication pipeline landscape

Name one indication; get its current Phase-3 drug pipeline mapped across every sponsor — each program tagged novel-agent vs repurposed-generic and overlaid with a cross-core publication-evidence maturity count — in one downloadable Excel matrix.

csv+1
9claims checked

Lecanemab is FDA-approved for early Alzheimer's disease. In its 18-month phase-3 trial it delayed cognitive and functional decline by ≈5 months versus…

clinical-evidencePrompt

Trust-filtered grounded answer

Ask a clinical question; get an answer where every sentence is pinned to a high-quality, non-retracted paper — and anything the evidence can't support is refused, not fabricated.

csv+1
10retracted papers
ranktitlejournalyear
1A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicineJournal of translational medicine2021
2Intra-articular injection in the knee of adipose derived stromal cells (stromal vascular fraction) and platelet rich plasma for osteoarthritisJournal of translational medicine2017
3Glioma gene therapy using induced pluripotent stem cell derived neural stem cellsMolecular pharmaceutics2011
research-integrityPrompt

Retraction hotspot scan

Name a research topic; get a checkable, downloadable list of the retracted papers Amass indexes on it — ranked by citation reach, with strict no-reason guardrails.

Get started

Bring cited evidence into your assistant.

Connect the Amass MCP once, then run any of these workflows on your own targets, with every answer traceable to source.

Data
No training on your data
Hosting
EU-hosted, enterprise
Isolation
Tenant-isolated by architecture
Certification
ISO 27001, SOC 2, NIS2: in motion